Our results showed that genetically proxied IL6R blockade was significantly related with a reduced risk of COPD (ORIVW = 0.71, 95% CI = 0.60–9.84) and asthma (ORIVW = 0.82, 95% CI = 0.74 − 0.90) (Fig. 2). The gene discussed is IL6R; the disease is asthma.